Biotech IV Monitor

MANE — Veradermics Incorporated

$4.6B market cap · 2 upcoming readouts tracked

Clinical trial readout dates for Veradermics Incorporated, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is December 2026.

Next readoutDecember 2026in ~1 month
Upcoming readouts22 Phase 3
Market cap$4.6B
Cash & investments$798M~38 quarters at last loss rate
Recent 8-K filings2latest 2026-11-10

Upcoming readouts

Phase 3 VDPHL01
Androgenetic Alopecia; AGA · NCT06972264
December 2026
Ongoing
Phase 3 VDPHL01 QD
Androgenetic Alopecia (AGA); Androgenetic Alopecia · NCT07146022
June 2027
Ongoing

Cash position

Veradermics Incorporated reported $798M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $21M; at that rate the cash would last about 38 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-10
8-K Other Events — often topline trial data2026-11-09

Discussion

No messages yet. If you follow MANE, you can start the conversation.
Track MANE in real time
See live implied volatility for MANE and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on MANE
Contact — questions or corrections about MANE: dukeupt@gmail.com